UCB (OTCMKTS:UCBJF) Reaches New 12-Month High – Time to Buy?

Shares of UCB SA (OTCMKTS:UCBJF) reached a new 52-week high on Thursday . The company traded as high as $330.39 and last traded at $330.39, with a volume of 44 shares traded. The stock had previously closed at $322.24.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on UCBJF shares. Stephens restated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research report on Monday, December 8th. Finally, Barclays reaffirmed an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy”.

UCB Stock Up 2.5%

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company has a fifty day moving average price of $298.47 and a two-hundred day moving average price of $272.22.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.